TriangleFOR PATIENTS · SOURCE READING
Targeted therapy for triple-negative breast cancer
Source: Targeted Therapy for Breast Cancer, National Cancer Institute.
Source updated: Not stated in this source · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
NCI patient treatment article for this disease Exact source article; not a clinically reviewed indication or current-standard recommendation.
Context: Targeted Therapy for Breast Cancer
Targeted therapy for triple-negative breast cancer
Triple-negative breast cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2 negative.
The targeted therapy drug sacituzumab govitecan may be used to treat triple-negative breast cancer.
Source links and citations
Learn more about Triple-Negative Breast Cancer Treatment.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice